Glow peptide side effects don't have reliable rates because no published study has tested the three-peptide blend itself. What matters is the safety record of each ingredient, the unknowns added by combining them, and the quality of the preparation. A short symptom list cannot answer all three.
Glow is a compounded blend — prepared by a pharmacy for a prescription — of BPC-157, TB-500, and GHK-Cu. These peptides are short chains of amino acids, the building blocks of proteins. Most evidence comes from animals or small human studies of related molecules. The Glow blend guide explains the ingredients; KLOW versus Glow explains how the blends differ.
Glow peptide side effects: what each ingredient tells us
The evidence belongs to individual ingredients, often studied by a different route. A skin cream, a treatment delivered into a vein, and a blend cannot share one safety record.
| Ingredient | What the evidence says | Component guide |
|---|---|---|
| BPC-157 | A 2025 pilot reported no side effects in two previously exposed adults; that is too small to establish safety. | BPC-157 side effects |
| TB-500 | FDA's July meeting briefing identified no human clinical studies of this fragment; trials of its parent protein are different evidence. | TB-500 side effects |
| GHK-Cu | FDA describes limited human injection data and possible immune reactions; experience with skin products cannot establish injection safety. | GHK-Cu side effects |
As of October 1, 2026, the day this article was written, a review published August 11 reinforces that gap. The American Journal of Sports Medicine review covers these ingredients alongside other compounds. Its abstract describes mostly animal research and sparse human studies, often without strong comparison groups. It does not supply safety rates for Glow.
“Nothing happened in a small study” and “this is safe over months” are very different conclusions. Pregnancy, breastfeeding, long-term use, and interactions remain important unanswered questions for the blend.
The copper question with GHK-Cu
GHK-Cu carries copper, but the full weight of GHK-Cu is not copper. A 2020 laboratory study in Biomolecules confirmed one copper atom bound to one GHK molecule. That tells us about the chemistry, not a safe amount for a person.
The NIH copper fact sheet lists the adult upper intake level, set by the Food and Nutrition Board, at 10 milligrams (10,000 micrograms) daily from food and supplements. An upper intake level is the highest usual daily intake unlikely to cause harm in healthy people. It is a nutrition limit for copper swallowed, not a limit for other routes or a Glow dosing guideline.
No blend study establishes how its copper affects blood levels or long-term health. Actual copper exposure depends on the formulation and amount administered. Wilson disease, an inherited condition that prevents normal copper clearance, makes this question especially important. Liver history and copper-containing supplements also belong in the provider's review.
What combining three peptides adds
Three ingredients create more possible explanations for a reaction. A rash could relate to one peptide, another ingredient, or a preparation problem. Timing can suggest a connection, but cannot identify the cause alone. The same attribution problem appears with KLOW peptide side effects, where a fourth peptide is added.
The mixture's interactions have not been mapped in people. There is no established evidence that adding GHK-Cu makes BPC-157 or TB-500 safer, or that the blend reduces side effects.
FDA's BPC-157 briefing describes immune-response concerns, including peptide aggregation — molecules clumping together — and impurities. These are potential risks, not measured reaction rates for Glow.
Blood-vessel growth is another shared question. Angiogenesis means formation of new blood vessels. FDA's briefings discuss it in BPC-157 research and research on TB-500-related sequences. The ingredients' proposed jobs therefore overlap; they are not three completely separate pathways.
That does not establish that Glow causes cancer. It also does not settle safety for someone with a current or past cancer diagnosis. Cancer history gives the clinician a reason to examine these growth-related uncertainties closely.
Preparation quality is a separate safety question
If a preparation is injected, local soreness, redness, swelling, or bruising are possible. Allergy and infection are separate possibilities. These concerns do not provide a list of Glow's “most common” effects, because no blend trial has counted them.
The CDC's injection-safety guidance explains that contaminated equipment or medication can transmit bacterial and fungal infections, as well as infections carried in blood. A reaction therefore needs assessment of the preparation and handling, alongside the ingredients.
As of October 1, 2026, the day this article was written, CDC is investigating illnesses after compounded glutathione injections. Its September 15 page, updated September 11, links illnesses to likely elevated endotoxins — bacterial substances that can contaminate medication. Glutathione is a different ingredient from Glow, but the investigation shows why materials suitable for injection matter.
A prescribed route provides a named clinician and pharmacy, with records connecting the medication to its batch. That gives a report somewhere to go and a recall someone to trace. Follow-up still matters: pharmacy oversight does not fill the gaps in human safety data.
Why the TB-500 distinction matters
TB-500 is a short fragment of thymosin beta-4, a longer protein involved in cell movement. The names often get blurred online.
A 2010 trial by Ruff and colleagues in Annals of the New York Academy of Sciences enrolled 40 healthy volunteers. They received placebo — an inactive comparison treatment — or full-length thymosin beta-4 into a vein. The abstract reports infrequent mild or moderate adverse events and no serious events. Those findings belong to the parent protein, not the TB-500 fragment or Glow.
This is why a provider needs the actual ingredient identity, rather than a reassuring study attached to a similar name.
What FDA status does and does not settle
Glow is coming soon to Promise — add me to the list. It will be dispensed as a compounded medication, which is different from an FDA-approved product. The blend and its three components are not FDA-approved drug products. A licensed provider may still prescribe — that decision is between you and your doctor.
As of October 1, 2026, the day this article was written, FDA's July 23–24 meeting materials document reviews of BPC-157 and TB-500 as potential compounding ingredients. That ingredient review is separate from testing the finished Glow blend. It does not create a blend-specific side-effect table.
When a reaction needs medical attention
Trouble breathing, tongue or throat swelling, or fainting can signal a severe allergic reaction and require emergency care. Spreading redness, warmth, worsening pain, drainage, or fever warrant prompt assessment for skin infection.
Persistent nausea, headache, dizziness, or a recurring rash also belong in a conversation with the prescriber. They are symptoms to investigate, rather than established Glow effects to accept without question.
Useful details include the label, amount administered, timing, other medicines or supplements, and lot number — the identifier for the batch. Our guide to reporting peptide side effects explains the provider, pharmacy, and FDA reporting routes.
At Promise, a licensed provider reviews every request and not everyone qualifies. The review considers the whole history, including allergies, copper concerns, pregnancy, cancer history, and other medicines. Decisions about continuing or changing treatment belong in that clinical conversation.
